Highly sensitive detection of the PIK3CAH1047R mutation in colorectal cancer using a novel PCR-RFLP method

BackgroundThe PIK3CAH1047R mutation is considered to be a potential predictive biomarker for EGFR-targeted therapies. In this study, we developed a novel PCR-PFLP approach to detect the PIK3CAH1047R mutation in high effectiveness.MethodsA 126-bp fragment of PIK3CA exon-20 was amplified by PCR, digested with FspI restriction endonuclease and separated by 3 % agarose gel electrophoresis for the PCR-RFLP analysis. The mutant sequence of the PIK3CAH1047R was spiked into the corresponding wild-type sequence in decreasing ratios for sensitivity analysis. Eight-six cases of formalin-fixed paraffin-embedded colorectal cancer (CRC) specimens were subjected to PCR-RFLP to evaluate the applicability of the method.ResultsThe PCR-RFLP method had a capability to detect as litter as 0.4 % of mutation, and revealed 16.3 % of the PIK3CAH1047R mutation in 86 CRC tissues, which was significantly higher than that discovered by DNA sequencing (9.3 %). A positive association between the PIK3CAH1047R mutation and the patients’ age was first found, except for the negative relationship with the degree of tumor differentiation. In addition, the highly sensitive detection of a combinatorial mutation of PIK3CA, KRAS and BRAF was achieved using individual PCR-RFLP methods.ConclusionsWe developed a sensitive, simple and rapid approach to detect the low-abundance PIK3CAH1047R mutation in real CRC specimens, providing an effective tool for guiding cancer targeted therapy.

[1]  L. Mazzucchelli,et al.  Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  P. Gascón,et al.  Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab , 2011, Tumor Biology.

[3]  Sabine Tejpar,et al.  Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. , 2010, The Lancet. Oncology.

[4]  Francesca Molinari,et al.  PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. , 2009, Cancer research.

[5]  M. Loda,et al.  Polymerase chain reaction-based methods for the detection of mutations in oncogenes and tumor suppressor genes. , 1994, Human pathology.

[6]  Hidetoshi Inoko,et al.  Single nucleotide polymorphism detection by polymerase chain reaction-restriction fragment length polymorphism , 2007, Nature Protocols.

[7]  D. Jäger,et al.  [Systemic therapy for colorectal cancer]. , 2005, Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen.

[8]  R. Lothe,et al.  Epigenetic and genetic features of 24 colon cancer cell lines , 2013, Oncogenesis.

[9]  Charles Swanton,et al.  Genetic prognostic and predictive markers in colorectal cancer , 2011, Nature Reviews Cancer.

[10]  R. Henrique,et al.  High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer , 2013, BMC Cancer.

[11]  Jinyao Ning,et al.  Efficacy and toxicity of adding cetuximab to chemotherapy in the treatment of metastatic colorectal cancer: a meta-analysis from 12 randomized controlled trials , 2014, Tumor Biology.

[12]  Lewis C. Cantley,et al.  AKT/PKB Signaling: Navigating Downstream , 2007, Cell.

[13]  L. Borsu,et al.  AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants , 2015, Molecular Cancer Research.

[14]  S. Pauker,et al.  Summary of recommendations: The Evaluation of Genomic , 2022 .

[15]  G. Fucharoen,et al.  Known and new hemoglobin A2 variants in Thailand and implication for β-thalassemia screening. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[16]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[17]  Jianying Zhou,et al.  Clinical Features and Gene Mutations of Lung Cancer Patients 30 Years of Age or Younger , 2015, PloS one.

[18]  Masahiro Ito,et al.  A Rapid and Simple Detection Method for the BRAFT1796A Mutation in Fine-Needle Aspirated Thyroid Carcinoma Cells , 2004 .

[19]  B. Park,et al.  Mutation of the PIK3CA oncogene in human cancers , 2006, British Journal of Cancer.

[20]  E. Zwarthoff,et al.  Two Multiplex Assays That Simultaneously Identify 22 Possible Mutation Sites in the KRAS, BRAF, NRAS and PIK3CA Genes , 2010, PloS one.

[21]  Renzo Boldorini,et al.  Increased Detection Sensitivity for KRAS Mutations Enhances the Prediction of Anti-EGFR Monoclonal Antibody Resistance in Metastatic Colorectal Cancer , 2011, Clinical Cancer Research.

[22]  D. Lambrechts,et al.  PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer , 2009, Clinical Cancer Research.

[23]  Y. Nakagawa,et al.  A simple method of detecting K-ras point mutations in stool samples for colorectal cancer screening using one-step polymerase chain reaction/restriction fragment length polymorphism analysis. , 2002, Clinica chimica acta; international journal of clinical chemistry.

[24]  Victor Moreno,et al.  A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction , 2012, Gut.

[25]  W. Scheithauer,et al.  Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Zhangrun Xu,et al.  Detection of Low-Abundance KRAS Mutations in Colorectal Cancer Using Microfluidic Capillary Electrophoresis-Based Restriction Fragment Length Polymorphism Method with Optimized Assay Conditions , 2013, PloS one.

[27]  M. A. Marcello,et al.  mRNA BRAF expression helps to identify papillary thyroid carcinomas in thyroid nodules independently of the presence of BRAFV600E mutation. , 2012, Pathology, research and practice.

[28]  Mef Nilbert,et al.  The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis , 2014, Acta oncologica.

[29]  Y. Samuels,et al.  Oncogenic PI3K and its role in cancer , 2006, Current opinion in oncology.

[30]  Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes , 2013, BMC Cancer.

[31]  M. Schlaak,et al.  Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations , 2014, BMC Cancer.

[32]  J. Neumann,et al.  Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis , 2013, Virchows Archiv.

[33]  Zuyao Yang,et al.  Promising biomarkers for predicting the outcomes of patients with KRAS wild‐type metastatic colorectal cancer treated with anti‐epidermal growth factor receptor monoclonal antibodies: A systematic review with meta‐analysis , 2013, International journal of cancer.

[34]  A. Lièvre,et al.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.

[35]  Carlo Rago,et al.  Mutant PIK3CA promotes cell growth and invasion of human cancer cells. , 2005, Cancer cell.

[36]  J. L. Tang,et al.  PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  G. Luo,et al.  Clinical Significance of a Point Mutation in DNA Polymerase Beta (POLB) Gene in Gastric Cancer , 2015, International journal of biological sciences.

[38]  G. Fucharoen,et al.  High resolution melting analytical platform for rapid prenatal and postnatal diagnosis of β-thalassemia common among Southeast Asian population. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[39]  Ji Luo,et al.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.

[40]  S. Erdamar,et al.  Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS , 2014, Tumor Biology.

[41]  P. Ross,et al.  The role of the PI3K pathway in colorectal cancer. , 2015, Critical reviews in oncology/hematology.

[42]  Jim F Huggett,et al.  Considerations for digital PCR as an accurate molecular diagnostic tool. , 2015, Clinical chemistry.

[43]  S. Gallinger,et al.  Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma. , 2006, Journal of the American College of Surgeons.

[44]  A. Wu,et al.  KRAS mutation detection in colorectal cancer by a commercially available gene chip array compares well with Sanger sequencing. , 2011, Clinica chimica acta; international journal of clinical chemistry.